SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin rises on acquiring 100% equity stake in Medquímica in Brazil

15 May 2015 Evaluate

Lupin is currently trading at Rs. 1681.50, up by 48.70 points or 2.98% from its previous closing of Rs. 1632.80 on the BSE.

The scrip opened at Rs. 1640.00 and has touched a high and low of Rs. 1684.60 and Rs. 1637.00 respectively. So far 98,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 903.95 on 27-May-2014.

Last one week high and low of the scrip stood at Rs. 1803.00 and Rs. 1589.40 respectively. The current market cap of the company is Rs. 75,630.00 crore.

The promoters holding in the company stood at 46.63% while Institutions and Non-Institutions held 43.36% and 10.01% respectively.

Lupin has acquired 100% equity stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica) subject to certain closing conditions. The acquisition marks Lupin’s foray into the high growth Brazilian market and would also shore up its position in the Latin American pharmaceuticals market given the company’s acquisition of Laboratorios Grin in Mexico last fiscal.

Incorporated in 1975, Medquímica is a broad based pharmaceutical company engaged in the development, manufacturing & commercialization of branded generics, pure generics and OTC products. Medquimica is one of the fastest growing companies in the Brazilian branded generics market and a trusted brand with the distribution channel in Brazil.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×